Intralesional Bleomycin for Treatment of a Recalcitrant Wart in an
Immunocompromised Patient: A Safe, Effective, and Underutilized Therapy
- Tracy Ngo,
- Hannah Hwang,
- Bijal Amin,
- Steven Cohen
Abstract
Injectable bleomycin is infrequently used for recalcitrant warts despite
its efficacy, acceptable safety profile, and high patient satisfaction
compared to other treatment modalities. We present an immunocompromised
patient with a large recalcitrant wart successfully treated with
intralesional bleomycin to provide greater clinical exposure, training,
and practice with intralesional bleomycin.22 Sep 2021Submitted to Clinical Case Reports 24 Sep 2021Assigned to Editor
24 Sep 2021Submission Checks Completed
03 Oct 2021Reviewer(s) Assigned
19 Jan 2022Review(s) Completed, Editorial Evaluation Pending
19 Jan 2022Editorial Decision: Accept
